{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:17:35Z","timestamp":1791994655222,"version":"4.4.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>We report on a meta-analysis of Silexan, a proprietary active substance produced from <jats:italic>Lavandula angustifolia<\/jats:italic>, in subthreshold anxiety, mixed anxiety and depressive disorder (MADD), and generalized anxiety disorder (GAD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The present analyses are based on all currently completed 5 double-blind, randomized, placebo-controlled trials investigating Silexan in adult out-patients who received Silexan 1\u2009\u00d7\u200980\u00a0mg\/day or placebo for ten weeks according to random assignment (<jats:italic>n<\/jats:italic>\u2009=\u20091213). Efficacy was assessed based on the Hamilton Anxiety Rating Scale (HAMA), several anxiety self-rating scales, the Clinical Global Impression (CGI) scale, and the Short Form-36 (SF-36) health status questionnaire.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After ten weeks\u2019 treatment, Silexan was significantly superior to placebo in reducing the HAMA total score (including the psychic and somatic anxiety sub-scores) and self-rated anxiety. Based on a\u2009\u2265\u200950% HAMA total score reduction, the responder rate ratio was 1.34 favoring Silexan, and the rate ratio of subjects much or very much improved according to the CGI was 1.51. Silexan was also significantly superior in improving the physical and mental health summary scores of the SF-36. There were no significant between-group differences concerning the occurrence of adverse events (AEs), serious AEs, and premature withdrawal due to AEs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This meta-analysis demonstrates that Silexan exerts significant anxiolytic effects in subthreshold anxiety, GAD and MADD that were consistently reflected in investigator ratings and patient-reported outcomes, including improvement of health-related life-quality, while showing favorable tolerability and safety.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00406-022-01547-w","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T23:19:08Z","timestamp":1675120748000},"page":"1615-1628","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8914-2192","authenticated-orcid":false,"given":"Markus","family":"Dold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Bartova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Volz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Seifritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Schl\u00e4fke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"1547_CR1","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1177\/0004867418799453","volume":"52","author":"G Andrews","year":"2018","unstructured":"Andrews G, Bell C, Boyce P, Gale C, Lampe L, Marwat O, Rapee R, Wilkins G (2018) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Aust N Z J Psychiatry 52:1109\u20131172","journal-title":"Aust N Z J Psychiatry"},{"key":"1547_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyu063","volume":"18","author":"P Baldinger","year":"2015","unstructured":"Baldinger P, H\u00f6flich AS, Mitterhauser M, Hahn A, Rami-Mark C, Spies M, Wadsak W, Lanzenberger R, Kasper S (2015) Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. Int J Neuropsychopharmacol 18:1\u20139","journal-title":"Int J Neuropsychopharmacol"},{"key":"1547_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/978-981-32-9705-0_19","volume":"1191","author":"B Bandelow","year":"2020","unstructured":"Bandelow B (2020) Current and novel psychopharmacological drugs for anxiety disorders. Adv Exp Med Biol 1191:347\u2013365","journal-title":"Adv Exp Med Biol"},{"key":"1547_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","volume":"17","author":"B Bandelow","year":"2015","unstructured":"Bandelow B, Michaelis S (2015) Epidemiology of anxiety disorders in the 21st century. Dial Clin Neurosci 17:327\u2013335","journal-title":"Dial Clin Neurosci"},{"key":"1547_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","volume":"19","author":"B Bandelow","year":"2017","unstructured":"Bandelow B, Michaelis S, Wedekind D (2017) Treatment of anxiety disorders. Dial Clin Neurosci 19:93\u2013107","journal-title":"Dial Clin Neurosci"},{"key":"1547_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/13651501.2012.667114","volume":"16","author":"B Bandelow","year":"2012","unstructured":"Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, M\u00f6ller HJ (2012) Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16:77\u201384","journal-title":"Int J Psychiatry Clin Pract"},{"key":"1547_CR7","doi-asserted-by":"crossref","unstructured":"Bandelow B, Werner AM, Kopp I, Rudolf S, Wiltink J, Beutel ME (2021) The German Guidelines for the treatment of anxiety disorders: first revision. Eur Arch Psychiatry Clin Neurosci 1\u201312","DOI":"10.1007\/s00406-021-01324-1"},{"key":"1547_CR8","doi-asserted-by":"crossref","unstructured":"Bartova L, Dold M, Volz HP, Seifritz E, M\u00f6ller HJ, Kasper S (2022) Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited. Eur Arch Psychiatry Clin Neurosci","DOI":"10.1007\/s00406-022-01390-z"},{"key":"1547_CR9","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","volume":"27","author":"U Bonnet","year":"2017","unstructured":"Bonnet U, Scherbaum N (2017) How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 27:1185\u20131215","journal-title":"Eur Neuropsychopharmacol"},{"key":"1547_CR10","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/sim.7141","volume":"36","author":"DL Burke","year":"2017","unstructured":"Burke DL, Ensor J, Riley RD (2017) Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med 36:855\u2013875","journal-title":"Stat Med"},{"key":"1547_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/16506073.2018.1560358","volume":"49","author":"E Carl","year":"2020","unstructured":"Carl E, Witcraft SM, Kauffman BY, Gillespie EM, Becker ES, Cuijpers P, Van Ameringen M, Smits JAJ, Powers MB (2020) Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials. Cogn Behav Ther 49:1\u201321","journal-title":"Cogn Behav Ther"},{"key":"1547_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.cpr.2004.06.001","volume":"24","author":"KA Collins","year":"2004","unstructured":"Collins KA, Westra HA, Dozois DJ, Burns DD (2004) Gaps in accessing treatment for anxiety and depression: challenges for the delivery of care. Clin Psychol Rev 24:583\u2013616","journal-title":"Clin Psychol Rev"},{"key":"1547_CR13","first-page":"100","volume":"17","author":"L Covi","year":"1981","unstructured":"Covi L, Rickels K, Lipman RS, McNair DM, Smith VK, Downing R, Kahn R, Fisher S (1981) Effects of psychotropic agents on primary depression. Psychopharmacol Bull 17:100\u2013103","journal-title":"Psychopharmacol Bull"},{"key":"1547_CR14","unstructured":"Deeks JJ, Higgins JPT, Altman DG (2020) Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds.) Cochrane handbook for systematic reviews of interventions version 6.1 (updated September 2020). The Cochrane Collaboration. http:\/\/www.training.cochrane.org\/handbook. Updated Sept 2020"},{"key":"1547_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2019.153099","volume":"65","author":"D Donelli","year":"2019","unstructured":"Donelli D, Antonelli M, Bellinazzi C, Gensini GF, Firenzuoli F (2019) Effects of lavender on anxiety: a systematic review and meta-analysis. Phytomedicine 65:153099","journal-title":"Phytomedicine"},{"key":"1547_CR16","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1124\/dmd.112.050203","volume":"41","author":"O Doroshyenko","year":"2013","unstructured":"Doroshyenko O, Rokitta D, Zadoyan G, Klement S, Schl\u00e4fke S, Dienel A, Gramatt\u00e9 T, L\u00fcck H, Fuhr U (2013) Drug cocktail interaction study on the effect of the orally administered lavender oil preparation Silexan on cytochrome P-450 enzymes in healthy volunteers. Drug Metab Dispos 41:987\u2013993","journal-title":"Drug Metab Dispos"},{"key":"1547_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045125320970325","volume":"10","author":"GA Fava","year":"2020","unstructured":"Fava GA (2020) May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. Ther Adv Psychopharmacol 10:1\u201311","journal-title":"Ther Adv Psychopharmacol"},{"key":"1547_CR18","doi-asserted-by":"publisher","first-page":"19com12794","DOI":"10.4088\/JCP.19com12794","volume":"80","author":"GA Fava","year":"2019","unstructured":"Fava GA, Cosci F (2019) Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs. J Clin Psychiatry 80:19com12794","journal-title":"J Clin Psychiatry"},{"key":"1547_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/13651501.2017.1301488","volume":"21","author":"M Gastpar","year":"2017","unstructured":"Gastpar M, M\u00fcller WE, Volz HP, M\u00f6ller HJ, Schl\u00e4fke S, Dienel A, Kasper S (2017) Silexan does not cause withdrawal symptoms even when abruptly discontinued. Int J Psychiatry Clin Pract 21:177\u2013180","journal-title":"Int J Psychiatry Clin Pract"},{"key":"1547_CR20","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.4103\/0019-5545.196975","volume":"59","author":"S Gautam","year":"2017","unstructured":"Gautam S, Jain A, Gautam M, Vahia VN, Gautam A (2017) Clinical practice guidelines for the management of generalised anxiety disorder (GAD) and panic disorder (PD). Indian J Psychiatry 59:S67\u2013S73","journal-title":"Indian J Psychiatry"},{"key":"1547_CR21","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD Diseases and Injuries Collaborators, 2020","year":"2020","unstructured":"GBD Diseases and Injuries Collaborators, 2020 (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396:1204\u20131222","journal-title":"Lancet"},{"key":"1547_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/JCP.0000000000000615","volume":"37","author":"MB Generoso","year":"2017","unstructured":"Generoso MB, Soares A, Taiar IT, Cordeiro Q, Shiozawa P (2017) Lavender oil preparation (Silexan) for treating anxiety: an updated meta-analysis. J Clin Psychopharmacol 37:115\u2013117","journal-title":"J Clin Psychopharmacol"},{"key":"1547_CR23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","volume":"19","author":"AF Gomez","year":"2018","unstructured":"Gomez AF, Barthel AL, Hofmann SG (2018) Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin Pharmacother 19:883\u2013894","journal-title":"Expert Opin Pharmacother"},{"key":"1547_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrd4075","volume":"12","author":"G Griebel","year":"2013","unstructured":"Griebel G, Holmes A (2013) 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 12:667\u2013687","journal-title":"Nat Rev Drug Discov"},{"key":"1547_CR25","doi-asserted-by":"publisher","first-page":"S544","DOI":"10.1016\/S0924-9338(09)70777-1","volume":"24","author":"O Grigorova","year":"2009","unstructured":"Grigorova O (2009) P01\u2013156 Estimation of placebo effect in therapy of generalized anxiety disorder. Eur Psychiatry 24:S544","journal-title":"Eur Psychiatry"},{"key":"1547_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50\u201355","journal-title":"Br J Med Psychol"},{"key":"1547_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5694\/mja14.00297","volume":"202","author":"MG Harris","year":"2015","unstructured":"Harris MG, Hobbs MJ, Burgess PM, Pirkis JE, Diminic S, Siskind DJ, Andrews G, Whiteford HA (2015) Frequency and quality of mental health treatment for affective and anxiety disorders among Australian adults. Med J Aust 202:185\u2013189","journal-title":"Med J Aust"},{"key":"1547_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40268-014-0065-5","volume":"14","author":"D Heger-Mahn","year":"2014","unstructured":"Heger-Mahn D, Pabst G, Dienel A, Schl\u00e4fke S, Klipping C (2014) No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol\/levonorgestrel combination. Drugs R D 14:265\u2013272","journal-title":"Drugs R D"},{"key":"1547_CR29","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/0269881107076996","volume":"21","author":"RB Hidalgo","year":"2007","unstructured":"Hidalgo RB, Tupler LA, Davidson JR (2007) An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 21:864\u2013872","journal-title":"J Psychopharmacol"},{"key":"1547_CR30","doi-asserted-by":"crossref","unstructured":"Kang H-J, Nam ES, Lee Y, Kim M (2019) How strong is the evidence for the anxiolytic efficacy of lavender?: Systematic review and meta-analysis of randomized controlled trials. Asian Nurs Res (Korean Soc Nurs Sci) 13:295\u2013305","DOI":"10.1016\/j.anr.2019.11.003"},{"key":"1547_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13651500600552297","volume":"10","author":"S Kasper","year":"2006","unstructured":"Kasper S (2006) Anxiety disorders: under-diagnosed and insufficiently treated. Int J Psychiatry Clin Pract 10:3\u20139","journal-title":"Int J Psychiatry Clin Pract"},{"key":"1547_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10354-015-0360-y","volume":"165","author":"S Kasper","year":"2015","unstructured":"Kasper S (2015) Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials. Wien Med Wochenschr 165:217\u2013228","journal-title":"Wien Med Wochenschr"},{"key":"1547_CR33","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.euroneuro.2015.07.024","volume":"25","author":"S Kasper","year":"2015","unstructured":"Kasper S, Anghelescu I, Dienel A (2015) Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep\u2014a randomized, placebo-controlled trial. Eur Neuropsychopharmacol 25:1960\u20131967","journal-title":"Eur Neuropsychopharmacol"},{"key":"1547_CR34","unstructured":"Kasper S, Dienel A (2015) Effects of Silexan on daily living skills and health related quality of life in patients with generalized anxiety disorder\u2014results from a randomized, double-blind, placebo controlled trial, Annual Congress of the German Society for Psychiatry and Psychotherapy (DGPPN), Berlin, Germany"},{"key":"1547_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/YIC.0b013e32833b3242","volume":"25","author":"S Kasper","year":"2010","unstructured":"Kasper S, Gastpar M, M\u00fcller WE, Volz H-P, M\u00f6ller H-J, Dienel A, Schl\u00e4fke S (2010) Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of \u201csubsyndromal\u201d anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol 25:277\u2013287","journal-title":"Int Clin Psychopharmacol"},{"key":"1547_CR36","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1017\/S1461145714000017","volume":"17","author":"S Kasper","year":"2014","unstructured":"Kasper S, Gastpar M, M\u00fcller WE, Volz H-P, M\u00f6ller H-J, Schl\u00e4fke S, Dienel A (2014) Lavender oil preparation Silexan is effective in generalized anxiety disorder\u2014a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol 17:859\u2013869","journal-title":"Int J Neuropsychopharmacol"},{"key":"1547_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/YIC.0000000000000176","volume":"32","author":"S Kasper","year":"2017","unstructured":"Kasper S, M\u00f6ller H-J, Volz H-P, Schl\u00e4fke S, Dienel A (2017) Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set. Int Clin Psychopharmacol 32:195\u2013204","journal-title":"Int Clin Psychopharmacol"},{"key":"1547_CR38","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1080\/15622975.2017.1331046","volume":"19","author":"S Kasper","year":"2018","unstructured":"Kasper S, M\u00fcller WE, Volz H-P, M\u00f6ller H-J, Koch E, Dienel A (2018) Silexan in anxiety disorders: clinical data and pharmacological background. World J Biol Psychiatry 19:412\u2013420","journal-title":"World J Biol Psychiatry"},{"key":"1547_CR39","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.euroneuro.2015.12.002","volume":"26","author":"S Kasper","year":"2016","unstructured":"Kasper S, Volz H-P, Dienel A, Schl\u00e4fke S (2016) Efficacy of Silexan in mixed anxiety-depression\u2014a randomized, placebo-controlled trial. Eur Neuropsychopharmacol 26:331\u2013340","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"1547_CR40","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","volume":"14","author":"MA Katzman","year":"2014","unstructured":"Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M (2014) Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 14(Suppl. 1):S1","journal-title":"BMC Psychiatry"},{"key":"1547_CR41","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1055\/s-0030-1264952","volume":"76","author":"J Kehr","year":"2010","unstructured":"Kehr J, Yoshitake T, Koch E, Noeldner M (2010) Effects of intraperitoneal administration of Silexan, an essential oil from flowers of Lavandula angustifolia on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex of freely moving rats. Planta Med 76:1316","journal-title":"Planta Med"},{"key":"1547_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0165-0327(88)90072-9","volume":"14","author":"W Maier","year":"1988","unstructured":"Maier W, Buller R, Philipp M, Heuser I (1988) The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 14:61\u201368","journal-title":"J Affect Disord"},{"key":"1547_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/mpr.323","volume":"19","author":"LS Matza","year":"2010","unstructured":"Matza LS, Morlock R, Sexton C, Malley K, Feltner D (2010) Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder. Int J Methods Psychiatr Res 19:223\u2013232","journal-title":"Int J Methods Psychiatr Res"},{"key":"1547_CR44","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00406-017-0852-4","volume":"269","author":"H-J M\u00f6ller","year":"2019","unstructured":"M\u00f6ller H-J, Volz H-P, Dienel A, Schl\u00e4fke S, Kasper S (2019) Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci 269:183\u2013193","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1547_CR45","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jpsychires.2020.10.028","volume":"136","author":"H-J M\u00f6ller","year":"2021","unstructured":"M\u00f6ller H-J, Volz H-P, Seifritz E, M\u00fcller H, Kenntner-Mabiala R, Kaussner Y, Schoch S, Kasper S (2021) Silexan does not affect driving performance after single and multiple dose applications: results from a double-blind, placebo and reference-controlled study in healthy volunteers. J Psychiatr Res 136:543\u2013551","journal-title":"J Psychiatr Res"},{"key":"1547_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104899","volume":"143","author":"WE M\u00fcller","year":"2021","unstructured":"M\u00fcller WE, Sillani G, Schuwald A, Friedland K (2021) Pharmacological basis of the anxiolytic and antidepressant properties of Silexan\u00ae, an essential oil from the flowers of lavender. Neurochem Int 143:104899","journal-title":"Neurochem Int"},{"key":"1547_CR47","unstructured":"National Institute for Health and Care Excellence (NICE) (2019) Generalised anxiety disorder and panic disorder in adults: management"},{"key":"1547_CR48","unstructured":"National Institute of Mental Health (1970) 12\u2014CGI. Clinical global impressions. In: Guy W (ed) EDCEU assessment in psychopharmacology. U.S. National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, Md., pp 217\u2013222"},{"key":"1547_CR49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/JCP.0000000000001021","volume":"39","author":"RW Pies","year":"2019","unstructured":"Pies RW (2019) Antidepressant discontinuation: a tale of two narratives. J Clin Psychopharmacol 39:185\u2013188","journal-title":"J Clin Psychopharmacol"},{"key":"1547_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c221","volume":"340","author":"RD Riley","year":"2010","unstructured":"Riley RD, Lambert PC, Abo-Zaid G (2010) Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340:c221","journal-title":"BMJ"},{"key":"1547_CR51","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/da.22433","volume":"32","author":"BR Rutherford","year":"2015","unstructured":"Rutherford BR, Bailey VS, Schneier FR, Pott E, Brown PJ, Roose SP (2015) Influence of study design on treatment response in anxiety disorder clinical trials. Depress Anxiety 32:944\u2013957","journal-title":"Depress Anxiety"},{"key":"1547_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107402","volume":"204","author":"SB Sartori","year":"2019","unstructured":"Sartori SB, Singewald N (2019) Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 204:107402","journal-title":"Pharmacol Ther"},{"key":"1547_CR53","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1037\/a0026517","volume":"12","author":"AB Satpute","year":"2012","unstructured":"Satpute AB, Mumford JA, Naliboff BD, Poldrack RA (2012) Human anterior and posterior hippocampus respond distinctly to state and trait anxiety. Emotion 12:58\u201368","journal-title":"Emotion"},{"key":"1547_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.genhosppsych.2020.02.001","volume":"64","author":"AM Sayed","year":"2020","unstructured":"Sayed AM, Morsy S, Tawfik GM, Naveed S, Minh-Duc NT, Hieu TH, Ali ZA, Shinkar A, Doheim MF, Hashan MR, Huy NT (2020) The best route of administration of lavender for anxiety: a systematic review and network meta-analysis. Gen Hosp Psychiatry 64:33\u201340","journal-title":"Gen Hosp Psychiatry"},{"key":"1547_CR55","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1055\/s-0042-101868","volume":"49","author":"O Schjerning","year":"2016","unstructured":"Schjerning O, Pottegard A, Damkier P, Rosenzweig M, Nielsen J (2016) Use of Pregabalin\u2014a nationwide pharmacoepidemiological drug utilization study with focus on abuse potential. Pharmacopsychiatry 49:155\u2013161","journal-title":"Pharmacopsychiatry"},{"key":"1547_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059998","volume":"8","author":"AM Schuwald","year":"2013","unstructured":"Schuwald AM, N\u00f6ldner M, Wilmes T, Klugbauer N, Leuner K, M\u00fcller WE (2013) Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels. PLoS ONE 8:e59998","journal-title":"PLoS ONE"},{"key":"1547_CR57","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ijnp\/pyaa064","volume":"24","author":"E Seifritz","year":"2021","unstructured":"Seifritz E, M\u00f6ller H-J, Volz H-P, M\u00fcller WE, Hopyan T, Wacker A, Schl\u00e4fke S, Kasper S (2021) No abuse potential of Silexan in healthy recreational drug users: a randomized controlled trial. Int J Neuropsychopharmacol 24:171\u2013180","journal-title":"Int J Neuropsychopharmacol"},{"key":"1547_CR58","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jpsychires.2019.04.013","volume":"115","author":"E Seifritz","year":"2019","unstructured":"Seifritz E, Schl\u00e4fke S, Holsboer-Trachsler E (2019) Beneficial effects of Silexan on sleep are mediated by its anxiolytic effect. J Psychiatr Res 115:69\u201374","journal-title":"J Psychiatr Res"},{"key":"1547_CR59","first-page":"611","volume":"115","author":"A Str\u00f6hle","year":"2018","unstructured":"Str\u00f6hle A, Gensichen J, Domschke K (2018) The diagnosis and treatment of anxiety disorders. Dtsch Arztebl Int 115:611\u2013620","journal-title":"Dtsch Arztebl Int"},{"key":"1547_CR60","first-page":"1","volume":"27","author":"H-P Volz","year":"2021","unstructured":"Volz H-P, Saliger J, Kasper S, M\u00f6ller H-J, Seifritz E (2021) Subsyndromal generalised anxiety disorder: operationalisation and epidemiology\u2014a systematic literature survey. Int J Psychiatry Clin Pract 27:1\u201310","journal-title":"Int J Psychiatry Clin Pract"},{"key":"1547_CR61","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1997","volume":"11","author":"R von K\u00e4nel","year":"2021","unstructured":"von K\u00e4nel R, Kasper S, Bondolfi G, Holsboer-Trachsler E, H\u00e4ttenschwiler J, Hatzinger M, Imboden C, Heitlinger E, Seifritz E (2021) Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: a meta-analysis. Brain Behav 11:e01997","journal-title":"Brain Behav"},{"key":"1547_CR62","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473\u2013483","journal-title":"Med Care"},{"key":"1547_CR63","doi-asserted-by":"publisher","first-page":"18042","DOI":"10.1038\/s41598-019-54529-9","volume":"9","author":"WS Yap","year":"2019","unstructured":"Yap WS, Dolzhenko AV, Jalal Z, Hadi MA, Khan TM (2019) Efficacy and safety of lavender essential oil (Silexan) capsules among patients suffering from anxiety disorders: a network meta-analysis. Sci Rep 9:18042","journal-title":"Sci Rep"},{"key":"1547_CR64","doi-asserted-by":"publisher","first-page":"106204","DOI":"10.1016\/j.phrs.2022.106204","volume":"179","author":"W Zhang","year":"2022","unstructured":"Zhang W, Yan Y, Wu Y, Yang H, Zhu P, Yan F, Zhao R, Tian P, Wang T, Fan Q, Su Z (2022) Medicinal herbs for the treatment of anxiety: a systematic review and network meta-analysis. Pharmacol Res 179:106204","journal-title":"Pharmacol Res"},{"key":"1547_CR65","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361\u2013370","journal-title":"Acta Psychiatr Scand"},{"key":"1547_CR66","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0033-3182(71)71479-0","volume":"12","author":"WW Zung","year":"1971","unstructured":"Zung WW (1971) A rating instrument for anxiety disorders. Psychosomatics 12:371\u2013379","journal-title":"Psychosomatics"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-022-01547-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-022-01547-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-022-01547-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:03:22Z","timestamp":1693289002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-022-01547-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1547"],"URL":"https:\/\/doi.org\/10.1007\/s00406-022-01547-w","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"7 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MD has received travel grants and consultant\/speaker honoraria from Medizin Medien Austria and Janssen. Within the last three years, LB has received travel grants and consultant\/speaker honoraria from Medizin Medien Austria, Universimed, Schwabe Austria, Janssen and Angelini. Within the last three years, HPV has served as a consultant or on advisory boards for Astra\/Zeneca, Eli Lilly, Lundbeck, Pfizer, Schwabe, Janssen, Otsuka, Angelini, and Sage and has served on speakers\u2019 bureaus for Astra\/Zeneca, Eli Lilly, Lundbeck, Schwabe, Janssen, Bayer, Recordati and neuraxpharm. ES received in the last three years honoraria and grants for advice and educational lectures from Lundbeck Switzerland, Schwabe Switzerland and Germany, Janssen Switzerland, Otsuka Switzerland, Mepha Pharma Switzerland, Otsuka Pharma Switzerland, Ricordati Switzerland and Sunovion Pharma UK and Angelini. HJM has received grant\/research support, consulting fees and honoraria within the last years from AstraZeneca, Lundbeck, Otsuka, and Schwabe. SS is employee of Dr. Willmar Schwabe GmbH & Co. KG. SK has received grant\/research support from Lundbeck; he has served as a consultant or on advisory boards for Angelini, Biogen, Esai, Janssen, IQVIA, Lundbeck, Mylan, Recordati, Sage and Schwabe; and he has served on speakers bureaus for Aspen Farmaceutica S.A., Angelini, Biogen, Janssen, Lundbeck, Neuraxpharma, Recordati, Sage, Sanofi, Schwabe, Servier and Sun Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}